

Beyond the Guidelines: Investigator Perspectives on Current Cases, Clinical Issues and Ongoing Research in the Management of Lymphoma and Chronic Lymphocytic Leukemia

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- The results of the Phase III RESONATE-2 trial evaluating ibrutinib versus chlorambucil for patients aged 65 years or older with untreated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma without 17p deletion demonstrated that single-agent ibrutinib is superior to chlorambucil in terms of _____.

 - Progression-free survival (PFS)
 - Overall survival
 - Both a and b
 - Neither a nor b
- A study by Byrd and colleagues evaluating the Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) for patients with relapsed CLL demonstrated _____.

 - A high response rate in the overall patient population
 - A high response rate among patients with del(17p) disease
 - Both a and b
 - Neither a nor b
- The GAUSS study evaluated obinutuzumab versus _____ for patients with relapsed CD20-positive indolent B-cell non-Hodgkin lymphoma (NHL).

 - Bortezomib
 - Rituximab
 - Brentuximab vedotin
- The Phase III GADOLIN study of bendamustine with or without obinutuzumab for rituximab-refractory indolent NHL demonstrated a statistically significant improvement in PFS with the addition of obinutuzumab.

 - True
 - False
- The Phase II CheckMate 205 study evaluating the efficacy of nivolumab for relapsed/refractory classical Hodgkin lymphoma demonstrated a 6-month overall survival rate of approximately _____.

 - 60%
 - 80%
 - 100%
- Data from Nowakowski and colleagues demonstrated that, for patients with newly diagnosed diffuse large B-cell lymphoma, the addition of _____ to R-CHOP mitigated the negative effect of the non-GCB phenotype on outcomes.

 - Lenalidomide
 - Ifosfamide
 - Etoposide
- Recent data from Rummel and colleagues demonstrated a median PFS of approximately 5 years with _____ as up-front treatment for mantle cell lymphoma (MCL) with or without maintenance rituximab.

 - R-CHOP
 - Bendamustine/rituximab (BR)
 - R-hyper-CVAD
- The randomized Phase II Intergroup E1411 trial will evaluate BR or bortezomib/BR (BVR), both followed by rituximab maintenance therapy, versus BR or BVR followed by _____ as maintenance therapy for up-front MCL.

 - Observation
 - R² (lenalidomide/rituximab)
 - Neither a nor b

POST-TEST

Beyond the Guidelines: Investigator Perspectives on Current Cases, Clinical Issues and Ongoing Research in the Management of Lymphoma and Chronic Lymphocytic Leukemia

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

9. Co-expression of MYC and Bcl-2 as detected by immunohistochemistry in patients with diffuse large B-cell lymphoma is associated with _____.
- a. Poorer outcomes
 - b. Better outcomes
 - c. Neither a nor b; outcomes are not altered
10. Results from a trial for patients with relapsed ALK-positive lymphoma demonstrated an overall response rate of 91% with the ALK inhibitor _____.
- a. Alectinib
 - b. Ceritinib
 - c. Crizotinib